JP2024507929A - 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法 - Google Patents

多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法 Download PDF

Info

Publication number
JP2024507929A
JP2024507929A JP2023551669A JP2023551669A JP2024507929A JP 2024507929 A JP2024507929 A JP 2024507929A JP 2023551669 A JP2023551669 A JP 2023551669A JP 2023551669 A JP2023551669 A JP 2023551669A JP 2024507929 A JP2024507929 A JP 2024507929A
Authority
JP
Japan
Prior art keywords
polynucleotide sequence
seq
amino acid
sequence
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023551669A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024507929A5 (https=
Inventor
コールドウェル デニガー，ドリュー
ヴィクトリア ハートン，レンカ
ジェームス ニール クーパー，ローレンス
ジュ，ドンヒョン
シ，ヤオヤオ
ルー，アン
カルピオ，ビクター
コリンソン－パウツ，マシュー
Original Assignee
アラウノス セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アラウノス セラピューティクス インコーポレイテッド filed Critical アラウノス セラピューティクス インコーポレイテッド
Publication of JP2024507929A publication Critical patent/JP2024507929A/ja
Publication of JP2024507929A5 publication Critical patent/JP2024507929A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Polyethers (AREA)
JP2023551669A 2021-02-25 2022-02-17 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法 Pending JP2024507929A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163153862P 2021-02-25 2021-02-25
US63/153,862 2021-02-25
US202163159434P 2021-03-10 2021-03-10
US63/159,434 2021-03-10
US202163260409P 2021-08-19 2021-08-19
US63/260,409 2021-08-19
US202163260855P 2021-09-02 2021-09-02
US63/260,855 2021-09-02
US202263267421P 2022-02-01 2022-02-01
US63/267,421 2022-02-01
PCT/US2022/070690 WO2022183167A1 (en) 2021-02-25 2022-02-17 Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024507929A true JP2024507929A (ja) 2024-02-21
JP2024507929A5 JP2024507929A5 (https=) 2025-02-25

Family

ID=80628943

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023551669A Pending JP2024507929A (ja) 2021-02-25 2022-02-17 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法

Country Status (8)

Country Link
US (1) US20240175047A1 (https=)
EP (1) EP4298121A1 (https=)
JP (1) JP2024507929A (https=)
KR (1) KR20230150336A (https=)
AU (1) AU2022227085A1 (https=)
CA (1) CA3209732A1 (https=)
IL (1) IL305393A (https=)
WO (1) WO2022183167A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4110804A1 (en) * 2020-02-26 2023-01-04 The United States of America, as represented by the Secretary, Department of Health and Human Services Hla class ii-restricted t cell receptors against ras with g12v mutation
US20250145950A1 (en) * 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells
US20250216381A1 (en) 2022-03-21 2025-07-03 Alaunos Therapeutics, Inc. Methods for Identifying Neoantigen-Reactive T Cell Receptors
WO2024059621A2 (en) * 2022-09-13 2024-03-21 The Trustees Of The University Of Pennsylvania T-cell receptors and compositions thereof for targeting mutant ras
WO2024163371A1 (en) * 2023-01-30 2024-08-08 Fred Hutchinson Cancer Center Binding proteins specific for mutant p53 and uses thereof
WO2024197072A2 (en) 2023-03-21 2024-09-26 Alaunos Therapeutics, Inc. Identification of neoantigen-reactive t cell receptors
WO2024206274A2 (en) * 2023-03-27 2024-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting y220c or r175h mutation in p53
CN117143823B (zh) * 2023-09-11 2024-07-16 皖南医学院第一附属医院（皖南医学院弋矶山医院） 一种基于tcr单链可变区的靶向ras(g12v)的嵌合抗原受体记忆nk细胞的研制及其应用
WO2025056681A1 (en) * 2023-09-15 2025-03-20 Medigene Immunotherapies Gmbh T-CELL RECEPTOR AGAINST mKRAS7-16 G12V AND G12C
WO2025096983A1 (en) * 2023-11-02 2025-05-08 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting tpx2 antigen and methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018226897A1 (en) * 2017-06-07 2018-12-13 Intrexon Corporation Expression of novel cell tags
WO2019160956A1 (en) * 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
WO2019209991A1 (en) * 2018-04-26 2019-10-31 Baylor College Of Medicine Immune effector cells and molecular adaptors with an antigen-cytokine complex for effective immunotherapy
WO2020106621A1 (en) * 2018-11-19 2020-05-28 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
ATE466948T1 (de) 1997-03-11 2010-05-15 Univ Minnesota Dns-basiertes transposon-system für die einführung von nucleinsäure in die dns einer zelle
GB9809658D0 (en) 1998-05-06 1998-07-01 Celltech Therapeutics Ltd Biological products
IL127142A0 (en) 1998-11-19 1999-09-22 Yeda Res & Dev Immune cells having predefined biological specificity
WO2000063374A1 (en) 1999-04-16 2000-10-26 Celltech Therapeutics Limited Synthetic transmembrane components
IL160359A0 (en) 2001-08-31 2004-07-25 Avidex Ltd Soluble t cell receptor
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
WO2003089618A2 (en) 2002-04-22 2003-10-30 Regents Of The University Of Minnesota Transposon system and methods of use
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
ATE475669T1 (de) 2004-06-29 2010-08-15 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
GB0712670D0 (en) 2007-06-29 2007-08-08 King S College London Isolated peptides and uses thereof
EP2160461B1 (en) 2007-07-04 2012-08-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Hyperactive variants of the transposase protein of the transposon system sleeping beauty
EP2486049A1 (en) 2009-10-06 2012-08-15 The Board Of Trustees Of The UniversityOf Illinois Human single-chain t cell receptors
CA3285826A1 (en) 2012-02-22 2026-03-02 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
PT2692865E (pt) 2012-07-30 2015-02-06 Nbe Therapeutics Llc Identificação mediada por transposição de proteínas funcionais ou de ligação específicas
CN118994363A (zh) 2014-11-26 2024-11-22 美国卫生和人力服务部 抗突变的kras的t细胞受体
KR102615825B1 (ko) 2015-03-11 2023-12-21 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 전위효소 폴리펩타이드 및 이의 용도
ES2879287T3 (es) 2015-09-15 2021-11-22 Us Health Receptores de células T que reconocen KRAS mutado restringido a HLA-cw8
HRP20221183T1 (hr) 2016-08-02 2022-12-09 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services T-stanični receptori anti-kras-g12d
KR20200003913A (ko) 2017-05-10 2020-01-10 이오반스 바이오테라퓨틱스, 인크. 액상 종양으로부터의 종양 침윤 림프구의 확장 및 그의 치료 용도
EP3673053A1 (en) 2017-08-21 2020-07-01 EMBL European Molecular Biology Laboratory Improved transposase polypeptide and uses thereof
KR20250037592A (ko) 2017-09-20 2025-03-17 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 돌연변이된 ras에 대한 hla 클래스 ii-제한된 t 세포 수용체
SG11202002635RA (en) 2017-09-29 2020-04-29 The United States Of America As Represented By The Secretary Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
WO2019067243A1 (en) 2017-09-29 2019-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T CELL RECEPTORS RECOGNIZING P53 MUTE
AU2018345400B2 (en) 2017-10-05 2024-06-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for selectively expanding cells expressing a TCR with a murine constant region
CR20200287A (es) 2017-12-04 2020-11-11 Us Health Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado
WO2019213195A1 (en) 2018-05-01 2019-11-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors which recognize mutated egfr
CA3116749A1 (en) 2018-10-24 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla-a3-restricted t cell receptors against mutated ras
EP3914612A1 (en) 2019-01-22 2021-12-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Hla class ii-restricted t cell receptors against ras with g12r mutation
TW202525841A (zh) 2019-06-27 2025-07-01 美國衛生與公眾服務部 識別p53中之r175h或y220c突變之t細胞受體
CN115279784A (zh) 2020-02-12 2022-11-01 美国卫生和人力服务部 针对含有g12d突变的ras的hla i类限制性t细胞受体
KR20220143875A (ko) 2020-02-14 2022-10-25 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 G12v 돌연변이를 갖는 ras에 대한 hla 클래스 i-제한된 t 세포 수용체
EP4110804A1 (en) 2020-02-26 2023-01-04 The United States of America, as represented by the Secretary, Department of Health and Human Services Hla class ii-restricted t cell receptors against ras with g12v mutation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018226897A1 (en) * 2017-06-07 2018-12-13 Intrexon Corporation Expression of novel cell tags
WO2019160956A1 (en) * 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
WO2019209991A1 (en) * 2018-04-26 2019-10-31 Baylor College Of Medicine Immune effector cells and molecular adaptors with an antigen-cytokine complex for effective immunotherapy
WO2020106621A1 (en) * 2018-11-19 2020-05-28 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction

Also Published As

Publication number Publication date
IL305393A (en) 2023-10-01
AU2022227085A1 (en) 2023-09-14
US20240175047A1 (en) 2024-05-30
KR20230150336A (ko) 2023-10-30
WO2022183167A1 (en) 2022-09-01
CA3209732A1 (en) 2022-09-01
EP4298121A1 (en) 2024-01-03

Similar Documents

Publication Publication Date Title
JP2024507929A (ja) 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法
US20230220097A1 (en) Treatment and prevention of cancer using virus-specific immune cells expressing chimeric antigen receptors
JP2021090444A (ja) 改変キメラ抗原受容体（ｃａｒ）ｔ細胞のヒト応用
WO2020131547A1 (en) Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
TW202039831A (zh) 對抗ｐｄ－１抗體呈現難治性之非小細胞肺癌（ｎｓｃｌｃ）病患之治療
CA3131305A1 (en) Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
US20240376429A1 (en) Virus-specific immune cells expressing chimeric antigen receptors
CA3107515A1 (en) Method for tumor treatment with immune effector cells
TW202334400A (zh) 表現il-10及嵌合抗原受體之cd4+ t細胞及其用途
JPWO2018143454A1 (ja) 新規ｔ細胞受容体
JP5911810B2 (ja) 制御性ｔ細胞の製造方法
US20250145950A1 (en) Methods for Activation and Expansion of T Cells
WO2023102328A2 (en) Treatment of cd30-positive cancer
CN117098772A (zh) 包含多顺反子表达盒的重组载体及其使用方法
WO2023249071A1 (ja) Ｔ細胞受容体
WO2026015450A1 (en) Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof
TW202611295A (zh) 表現ｉｌ－１０及嵌合抗原受體之ｃｄ４＋ｔ細胞及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260303